Predictive modeling and reliable biomarker discovery in clinical omics studies
Predictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.
Julien Hédou
CEO, SurgeCare
Julien Hédou studied Engineering at Ecole Polytechnique (Paris) before completing his MS in Biomedical Informatics degree from Stanford University. Julien has been working on developing the machine learning pipelines of the Gaudillière lab that integrates high parameter mass cytometry and proteomics using sparse machine learning approaches to identify biologically plausible and reliable predictive biomarkers, focusing on several clinical scenarios: 1) immune mechanisms of surgical recovery and complications, 2) feto-maternal health outcomes, including preterm birth, preeclampsia and endometriosis, 3) immune dysfunction and outcomes prediction in patients with acute ischemic stroke. Julien Hédou is now CEO of SurgeCare, a life science company that commercializes, PreCyte®, for predicting the risk of postoperative complications, and its laboratory services, SurgeLab™, for acquiring individualized immune signatures and analyzing multiomic datasets.
Predictive modeling and reliable biomarker discovery in clinical omics studies
A presentation by Julien Hédou
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.